CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg. Discontinuations from renovascular AEs , although less common than discontinuations from GI AEs , were significantly higher with etoricoxib .
O O B-ChemicalEntity O O O O O O O O O O O O B-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature O O B-ChemicalEntity O O O O O O O O O O O O O B-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature O O O O O B-ChemicalEntity O